Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1986 1
1998 1
1999 3
2001 1
2002 2
2003 1
2005 4
2007 1
2009 2
2010 2
2011 3
2012 4
2013 5
2014 3
2015 1
2016 4
2017 2
2019 5
2020 4
2021 2
2022 2
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC; Karlan BY, Khan S, Klein C, Kohlmann W; CGC; Kurian AW, Laronga C, Litton JK, Mak JS; LCGC; Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC; Senter-Jamieson L; CGC; Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Daly MB, et al. J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001. J Natl Compr Canc Netw. 2021. PMID: 33406487
Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic ca …
Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consid …
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Flaig TW, et al. J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. J Natl Compr Canc Netw. 2020. PMID: 32135513
Some important updates include recommendations for optimal treatment of non-muscle-invasive bladder cancer in the event of a bacillus Calmette-Guerin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations …
Some important updates include recommendations for optimal treatment of non-muscle-invasive bladder cancer in the event of a bacillus Calmet …
Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. de Kouchkovsky I, et al. Prostate. 2024 Apr;84(5):426-440. doi: 10.1002/pros.24664. Epub 2024 Jan 3. Prostate. 2024. PMID: 38173302 Review.
BACKGROUND: Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration-resistant disease invariably develops. ...CONCLUSIONS: Recent advances in genomic and molecular classification of NEPC and the development …
BACKGROUND: Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration …
Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.
Ip E, Young AL, Scheinberg T, Harrison M, Beale P, Goodwin A. Ip E, et al. Asia Pac J Clin Oncol. 2022 Oct;18(5):e414-e419. doi: 10.1111/ajco.13741. Epub 2022 Jan 30. Asia Pac J Clin Oncol. 2022. PMID: 35098668
Written and electronic medical records were reviewed until August 2019 to assess patient and family history characteristics, genetic testing eligibility, results and posttest management for women who had testing coordinated via mainstreaming or by the CGS. ...CGS was more …
Written and electronic medical records were reviewed until August 2019 to assess patient and family history characteristics, genetic …
Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB. Shah RB. Adv Anat Pathol. 2013 Mar;20(2):117-24. doi: 10.1097/PAP.0b013e3182862ac5. Adv Anat Pathol. 2013. PMID: 23399797 Review.
TMPRSS2:ERG gene fusions, the most common molecular subtype of ETS family gene fusions occur in ~50% of prostate carcinomas (PCas) and ~20% of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical …
TMPRSS2:ERG gene fusions, the most common molecular subtype of ETS family gene fusions occur in ~50% of prostate carcinomas …
Prostate cancer: the new evidence base for diagnosis and treatment.
Lamb DS, Slaney D, Smart R, Nacey JN, Russell G, Scott B, Johnson CA, Adams JD, Moran S, Delahunt B. Lamb DS, et al. Pathology. 2007 Dec;39(6):537-44. doi: 10.1080/00313020701684458. Pathology. 2007. PMID: 18027255 Review.
Although prostate cancer (PC) has a significant mortality, there is debate regarding the utility of PC screening. ...Modern histopathological assessment of fine core needle biopsies of the prostate allows for the likely behaviour of cancer present to be accurately p …
Although prostate cancer (PC) has a significant mortality, there is debate regarding the utility of PC screening. ...Modern histopath …
Management Strategies and Patient Selection After a Hospital Funding Reform for Prostate Cancer Surgery in Canada.
Wettstein MS, Palmer KS, Kulkarni GS, Paterson JM, Ling V, Lapointe-Shaw L, Li AH, Brown A, Taljaard M, Ivers N. Wettstein MS, et al. JAMA Netw Open. 2019 Aug 2;2(8):e1910505. doi: 10.1001/jamanetworkopen.2019.10505. JAMA Netw Open. 2019. PMID: 31469400 Free PMC article.
OBJECTIVE: To determine whether changes in hospital funding policy aimed at improving health care quality and value were associated with changes in the management of localized prostate cancer or the characteristics of patients receiving radical prostatectomy (RP) fo …
OBJECTIVE: To determine whether changes in hospital funding policy aimed at improving health care quality and value were associated w …
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Gillessen S, et al. Ann Oncol. 2015 Aug;26(8):1589-604. doi: 10.1093/annonc/mdv257. Epub 2015 Jun 3. Ann Oncol. 2015. PMID: 26041764 Free PMC article.
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The successful registration of several …
The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence …
Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.
Kushnir I, Kirk L, Mallick R, Kim RH, Graham GE, Breau RH, Lattouf JB, Violette PD, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, Heng DYC, Basappa NS, So A, Pouliot F, Reaume NM. Kushnir I, et al. Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e10-e15. doi: 10.1016/j.clon.2019.07.010. Epub 2019 Aug 1. Clin Oncol (R Coll Radiol). 2020. PMID: 31378448
AIMS: To evaluate the clinical impact of the Canadian criteria for identifying patients and families at risk for hereditary renal cell carcinoma (RCC). MATERIALS AND METHODS: The Canadian hereditary RCC risk criteria were applied to patients from 16 centres in the C …
AIMS: To evaluate the clinical impact of the Canadian criteria for identifying patients and families at risk for hereditary renal cel …
Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas.
Fraguas-Sánchez AI, Fernández-Carballido A, Torres-Suárez AI. Fraguas-Sánchez AI, et al. Expert Opin Investig Drugs. 2016 Nov;25(11):1311-1323. doi: 10.1080/13543784.2016.1236913. Epub 2016 Sep 28. Expert Opin Investig Drugs. 2016. PMID: 27633508 Review.
The term 'cannabinoids' designates a family of compounds with activity upon cannabinoid receptors. Cannabinoids are classified in three groups: phytocannabinoids, endocannabinoids, and the synthetic analogues of both groups. ...Areas covered: The aim of this review is to e …
The term 'cannabinoids' designates a family of compounds with activity upon cannabinoid receptors. Cannabinoids are classified in thr …
52 results